The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
NIBIB Exploratory Clinical Trials for Small Business (R44 Clinical Trial Required)
The purpose of this Funding Opportunity Announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Biomedical Imaging and Bioengineering (NIBIB). This Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of the NIBIB.
For this Funding Opportunity Announcement, the NIBIB will only support SBIR applications proposing early-stage clinical trials through Phase I, first-in-human, safety, feasibility or other small clinical trials that inform early-stage technology development. The NIBIB will not support applications proposing Phase II, III, IV or pivotal clinical trials or trials in which the primary outcome is efficacy, effectiveness or a post-market concern.
SBIR/STTR Deadlines: Sep. 5, Jan. 5, Apr. 5
PA-18-631 Expiration Date January 6, 2021
Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity.
According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards.